ABSTRACT
The Indian pharmaceuticals market is the third largest in terms of volume and thirteenth largest in terms of value. It has established itself as a global manufacturing and research hub. A large raw material base and the availability of a skilled workforce give the industry a definite competitive advantage. India has one of the lowest manufacturing costs in the world. The regulatory requirements of various countries of the world vary from each other. Therefore, it is challenging for Indian companies to develop a single drug that can be simultaneously submitted in all the countries for approval. The role of the regulatory authorities is to ensure the quality, safety, and efficacy of all medicines in circulation in their country. It not only includes the process of regulating and monitoring the drugs but also the process of manufacturing, distribution, and promotion of it. One of the primary challenges for regulatory authorities is to ensure that the pharmaceutical products are developed as per the regulatory requirement of that country. This process involves the assessment of critical parameters during product development. This article covers the processes involved and requirements like import-export code, technical documentation, filing and reviewing process of drug master file, certificate of pharmaceutical product, common technical document (CTD), eCTD, and ACTD, for the registration and approval of Indian drug products in the overseas market.

Keywords: Import Export Code, DMF, CTD, eCTD, ACTD.

INTRODUCTION
The Indian pharmaceutical industry is considered one of the fastest-growing sectors in the country and has exhibited considerable growth in recent years. It is one of the high-performing knowledge-based segments of the manufacturing sector. In addition to catering to the needs of the domestic demand, the pharmaceutical industry is also engaged in contract manufacturing, contract research, clinical trials, contract R&D, and direct exports to developing and developing country markets. The industry has an eminent position in the global pharmaceutical market and is one of the leading producers of generic pharmaceutical products in the world, catering to approximately one-fifth of the global generic Pharma market.1 The Indian Pharma Industry exports its products to more than 200 countries in the world, including strictly regulated markets such as the US, Europe, and Japan. Regulatory supervision and quality monitoring of medicines and other pharmaceutical products are of vital importance. In this context, this study examines the regulatory landscape in highly regulated markets of the US, the EU as well as that of India and then analyses the trend in the world and India’s international trade in pharmaceutical products and suggests select measures which could help the Indian industry move higher up the export growth trajectory. Due to the emerging regulatory needs of the pharmaceutical sector, the drug evaluation for the control of drug quality and trade has become highly sophisticated. Regulatory guidelines and standard tools provide a basis for the implementation of laws, whereas laws provide a legal basis for drug control. The world covers more than 100 countries, where most of them have established pharmaceutical legislations and regulatory requirements. For worldwide regulatory dossier submissions, it is a pre-requisite requirement to know country-specific guidelines and norms. Therefore, it is very important to analyse the differences and commonness between the regulatory requirements and pharmaceutical legislations of different countries of the world.2 The Pharmaceutical market is based on the diversity in the regulation region. Regulatory authorities of various countries are enlisted as follows:

Table 1: Illustrates the regulatory authorities of various countries

<table>
<thead>
<tr>
<th>Name of Country</th>
<th>Regulatory authority</th>
</tr>
</thead>
<tbody>
<tr>
<td>USA</td>
<td>USFDA</td>
</tr>
<tr>
<td>European Union (EU)</td>
<td>EMA</td>
</tr>
<tr>
<td>Canada</td>
<td>HPFB</td>
</tr>
<tr>
<td>Japan</td>
<td>PMDA</td>
</tr>
<tr>
<td>Australia</td>
<td>TGA</td>
</tr>
<tr>
<td>South Africa</td>
<td>MCC</td>
</tr>
<tr>
<td>LATAM (Brazil)</td>
<td>Independent regulatory agencies/ANVISA</td>
</tr>
</tbody>
</table>
Export highlights

- It is expected to grow by 30 percent to reach US$ 20 billion by the year 2020.
- In 2018-19, top importers of India’s pharmaceutical products were the USA (US$ 119.18 million), Russia (US$ 10.33 million), UK (US$ 9.83 million), South Africa (US$ 3.63 million), and Nigeria (US$ 1.71 million).
- India is expected to rank amongst the top three pharmaceutical markets in terms of incremental growth by 2020.
- India is the largest supplier of generic medicines globally (20 to 22 percent of global export volume).

Procedure for Export of Pharmaceutical Products

India’s Foreign Trade i.e., Exports and Imports are regulated by Foreign Trade Policy notified by Central Government in the exercise of powers conferred by section 5 of foreign trade (Development and Regulation) Act 1992. Presently Foreign Trade Policy 2015-20 is effective from 1st April 2015. As per FTD & R act, export is defined as an act of taking out of India any goods by land, sea, or air and with a proper transaction of money.

Steps involved in Export

Export in itself is a very wide concept and a lot of preparations are required by an exporter before starting an export business. To start an export business, the following steps may be followed:

1. Establishing an Organization
To start the export business, first, a Sole Proprietary concern/Partnership firm/Company has to be set up as per procedure with an attractive name and logo.

2. Opening a Bank Account
A current account with a bank authorized to deal in Foreign Exchange should be opened.

3. Obtaining Permanent Account Number (PAN)
Every exporter and importer must obtain a PAN from the Income Tax Department.

4. Obtaining Importer-Exporter Code (IEC) Number
- As per the Foreign Trade Policy, it is mandatory to obtain IEC for export/import from India. Para 2.05 of the FTP, 2015-20 lays down the procedure to be followed for obtaining an IEC, which is PAN-based.
- An application for IEC is filed online at www.dgft.gov.in as per ANF 2A, online payment of application fee of Rs. 500/- through net Banking or credit/debit card is made along with requisite documents as mentioned in the application form.

5. Registration cum membership certificate (RCMC)
For availing authorization to import/export or any other benefit or concession under FTP 2015-20, as also to avail the services/guidance, exporters are required to obtain RCMC granted by the concerned Export Promotion Councils/ FIEO/Commodity Boards/ Authorities.

6. Selection of Product
All items are freely exportable except few items appearing in the prohibited/restricted list.

7. Finding Buyers
Participation in trade fairs, buyer-seller meets, exhibitions, B2B portals, web browsing is effective tools to find buyers. EPC’s, Indian Missions abroad, overseas chambers of commerce can also be helpful. Creating a multilingual Website with a product catalogue, price, payment terms, and other related information would also help.
Sampling
Providing customized samples as per the demands of foreign buyers helps in getting export orders. As per FTP 2015-2020, exports of bonafide trade and technical samples of freely exportable items shall be allowed without any limit.

Pricing/Costing
Product pricing is crucial in getting buyers’ attention and promoting sales because of international competition. The price should be worked out taking into consideration all expenses from sampling to realization of export proceeds based on terms of sale i.e. Free on Board (FOB), Cost, Insurance & Freight (CIF), Cost & Freight(C&F), etc. The goal of establishing export costing should be to sell maximum quantity at a competitive price with maximum profit margin. Preparing an export costing sheet for every export product is advisable.

Negotiation with Buyers
After determining the buyer’s interest in the product, prospects, and continuity in business, demand for giving reasonable allowance/discount in price may be considered.

Covering Risks through ECGC
International trade involves payment risks due to buyer/Country insolvency. These risks can be covered by an appropriate Policy from Export Credit Guarantee Corporation Ltd (ECGC). Where the buyer is placing an order without making the advance payment or opening a Letter of Credit, it is advisable to procure a credit limit on the foreign buyer from ECGC to protect against the risk of non-payment.

Figure 1: Export Procedure

- Prepare a Business Plan
- Select a name for organization
- Registration under Company Act
- Product selection for Export
- Market Research
- Product Evaluation
- Registration with Director General of Foreign Trade to get IEC
- Registration with the relevant export promotion
- Registration with Sales Tax Office
- Registration with Export Credit Guarantee Corporation
- Registration with relevant Chamber of Commerce to get certification Origin
- Market Identification
- Need Analysis
- Channel Selection
- Agents/Distributors /Wholesalers/End Users/Sales Reps
- Identifying the Potential Buyers/Custonmers
- Trade Fairs/Internet/Personal Visits/Contacts/Agents
- Going for Procuring orders
- Agreeing upon pricing, freight charges, currency, delivery etc.
- Signing of contract
- Determining the payment terms
- Advance Payment/ Letter of Credit (LC) / Open Account
- Importer sends purchase order
- Production
- Packaging, Warehousing
- Certificate of quality control
- Final Payment Receives from Importer
- Submission of docs to bank
- Transportation Made by Marine / Air/ Road / Rail
Drug Master File (DMF)
A Drug Master File (DMF) is a submission to the Food and Drug Administration (FDA) that may be used to provide. Confidential details information about facilities, processes, or articles used in the manufacturing, processing, packaging, and storing of one or more human drugs. It’s important to note that the submission of a DMF is not required by law or FDA but is submitted by a sponsor completely at its discretion.

DMF has divided into 2 parts
Open part (Applicant’s part)
Contains all the required information related to a method of manufacture and a brief outline of a method of manufacture, potential impurities, manufacturing system, etc.

Closed Part (Restricted part):
Contains Confidential information on the manufacture of API like Extraction, validation, process, solvents used, reactions, temperature, conditions, critical steps in manufacture, etc.

Apart from this DMF is divided into 5 types

Type I DMF
A Type I DMF is recommended for a person outside of the United States to assist FDA in conducting on-site inspections of their manufacturing facilities. The DMF should describe the manufacturing site, equipment capabilities, and operational layout.

It contains information about the plant information like
- Manufacturing site.
- Equipment capabilities.
- Operational layout.
- Corporate headquarters.
- Site Address.

Type II DMF
Drug Substance, Drug Substance Intermediate, and Material used in their Preparation
Short summary of all significant steps involved in the manufacturing and control of drug intermediate or substance and detailed guidelines on what should be part Type II DMF

Type III DMF
It contains detailed information on the packaging material used. i.e.
- Intended use of the packing material.
- Composition of the packing material.
- Name of the suppliers.
- Specifications.
- Toxicological data if any such material available.

Type IV DMF
It includes information of each additives along with proper identification method, characterizing procedure, and test method and % composition. Toxicological data should be provided if any such material available.

Type V
All FDA accepted reference information. FDA discourages the use of Type V DMF’s for miscellaneous information, duplicate information, or information that should be included in one of the other types of DMF’s.

Common Technical Document (CTD)
Common Technical Document is an essential document to be submitted to the regulatory body as a supportive list of leaflets attached with the registration applications for pharmaceuticals to get market authorization. Mainly CTD tells about the format for the data.
DMF Submission and Reviewing Cycle

Figure 2: DMF Submission and Reviewing Cycle

CTD Triangle

Commonly, RA expert knows the documents to be submitted while getting approval for any drug product. But CTD mainly tells about the organization of the information in order. CTD documents should be clear, unambiguous, and transparent. Accordingly, it is having 5 modules.

- **Module 1: Administrative and prescribing information**
- **Module 2: Common Technical Document Summaries (Quality Overall summary)**
- **Module 3: Quality Data**
- **Module 4: Non-Clinical study reports**
- **Module 5: Clinical Study reports**

Table 2: Difference between CTD Dossier and DMF

<table>
<thead>
<tr>
<th>CTD Application (Dossier)</th>
<th>DMF Submission</th>
</tr>
</thead>
<tbody>
<tr>
<td>Must be filed by an applicant</td>
<td>Not mandatory to file DMF</td>
</tr>
<tr>
<td>Comes under the regulatory status</td>
<td>No such regulations</td>
</tr>
<tr>
<td>Each application and its supplements are entered into a common database</td>
<td>DMF’s are entered in a separate database as per the type</td>
</tr>
<tr>
<td>Submitted to intended review division</td>
<td>Submitted to Regulatory body</td>
</tr>
<tr>
<td>The review procedure is different than that of DMF</td>
<td>Reviewed only when referenced with NDA/ANDA applications</td>
</tr>
<tr>
<td>Approval timeline is there</td>
<td>No approval timeline</td>
</tr>
</tbody>
</table>
- CTD dossier should be detailed and easily acceptable by the regulatory authority.
- The documents should be arranged in such a way that they can be easily reviewed by the reviewer.
- Documents submitted should be signed and dated.
- Labelling should be mentioned as per the country's regulatory guidelines.
- Required documents should be submitted according to the checklist to avoid rejection of the application or queries which in turn speed up the review process and approval.
- The justification for certain tests should be mentioned and supportive documents should be attached.
- Once the dossier is prepared before sending it has to be checked and verified for any mistakes.
- While in the clinical study report (Module 5) CRF, all study reports should be attached.
- BMR is required not MFR.
- Some countries ask for validation certificates that should be up to date.
- Changes done in any batches should be notified and justified.
- Amendments, supplements should be submitted to the regulatory body.

**Electronic Common Technical Document (eCTD)**

eCTD is an electronic Common Technical Document, an electronic format where the information and document are submitted to the regulatory body electronically by using the software. Some of the eCTD software is Pharm ready, Edeos, etc. eCTD submission is for applications, amendments, variations, supplements, reports, Master formulae, etc. Understanding the eCTD format and applying successfully in submission is the biggest hurdle. While the sponsor or the applicant may face a problem when the documents do not fit into the format because the application or submission shall be bounced back known as technical rejection.  

Software using for eCTD application should be validated.

**Requirements of eCTD**

1. Copy and paste.
2. Verifying and printing documents.
4. Export of information to databases.

**Modular Structure of eCTD**

Overall structure of submission is defined by XML eCTD DTD (Document Type Definition). The XML file is the backbone for eCTD submission. The purpose of XML backbone is,

- To manage meta-data of the entire submission like information about submitting and receiving organization, manufacturer, ID, etc., and documents.
- To form a comprehensive table of contents and provide corresponding navigation aids.

**Common Formats of eCTD**

1. Narrative: Portable Document Format (PDF) [Calibri 12]
2. Structure: Extensible Mark-up Language (XML)
3. Graphic: Use PDF, whenever PDF is not supporting, use Joint Photographic Experts Group (JPEG), Portable Network Graphics (PNG), Scalable Vector Graphics (SVG), and Graphic Interchange Format (GIF).
4. Font size 9 and 10 are suggested for tables.

**Folder and File Naming Conventions**

- The maximum length of the name of a single folder or file is 64 characters.
- The folder name should be written in lower case only. For example: Study Report 1 should be written as study-report-1.
- The file should not exceed more than 2 GB
- Hyperlink- “Insert cross- Reference” feature in MS word is known as Hyperlinking
- Hyperlink improves the overall quality and accuracy of the complete file.
- eCTD will be submitted in Electronic Submission Gateway (ESG)
- All documents should be scanned properly which will help to recognize the file.
- Scanning will be done by using OCR software (Optical Character Recognition).
Advantages of eCTD
1. Reduced cost in producing, checking, and storage of paper documents
2. Easy to Review
3. Faster process
4. Greater search functionality
5. Easy to manage the dossier life cycle
6. Can reuse the documents
7. Easy to do any amendments
8. Reviewer is friendly in comparing the dossier with amendments.
9. Several people can read the documents at the same time.
10. More predictable format
12. Time-saving process

ASEAN Common Technical Document (ACTD)
ASEAN Common Technical Document (ACTD) ASEAN (Association of southeast Asian Nations) Common Technical Document (ACTD) is a structured document for the registration of pharmaceuticals in ASEAN countries.

Table 3: ASEAN countries and their regulatory bodies

<table>
<thead>
<tr>
<th>Country</th>
<th>Regulatory Body</th>
</tr>
</thead>
<tbody>
<tr>
<td>Indonesia</td>
<td>National Agency of Drug and Food Control (NADFC)</td>
</tr>
<tr>
<td>Vietnam</td>
<td>Drug Administration of Vietnam</td>
</tr>
</tbody>
</table>

ACTD includes 4 parts
Part 1: Table of Contents, Administrative data, and Product information
Section A: Introduction.
Section B: Overall ASEAN CTD Table of contents
Section C: Documents like registration application, product datasheet, prescribing information, and labelling.

Part 2: Quality Document
Section A: Table of Contents.
Section B: Quality Overall summary.
Section C: Body of Data.

Part 3: Non-clinical Document
Section A: Table of Contents.
Section B: Non-clinical Overview.
Section C: Non-clinical written and tabulated summaries.
- Pharmacology.
Part 4: Clinical document

Section A: Table of Contents

Section B: Clinical Overview

Section C: Clinical Summary

- Summary of Biopharmaceutics and Associated Analytical Methods.
- Summary of Clinical Pharmacology Studies.
- Summary of Clinical Efficacy.
- Summary of Clinical Safety.
- Synopses of Individual Studies.

Section D: Tabular Listing of All Clinical Studies. Section E: Clinical Study Reports.

Section F: List of Key Literature References.

The registration fee will differ from country to country. The documents shall be submitted to the particular regulatory authority. The documents related to drug substances and drug products and a new chemical entities will be according to the country’s requirements.18

**Table 4:** Differences between CTD/ eCTD/ ACTD19

<table>
<thead>
<tr>
<th>CTD</th>
<th>eCTD</th>
<th>ACTD</th>
</tr>
</thead>
<tbody>
<tr>
<td>Paper submission</td>
<td>Electronic (Using Software)</td>
<td>Paper or Electronic</td>
</tr>
<tr>
<td>Tedious and Difficult Review process</td>
<td>Faster review process</td>
<td>Depends upon the country</td>
</tr>
<tr>
<td>Bulk and Large documents</td>
<td>XML files storage will be in GB</td>
<td>Large documents</td>
</tr>
<tr>
<td>Includes 5 modules</td>
<td>5 modules</td>
<td>Includes 4 parts</td>
</tr>
<tr>
<td>Cross references include CTD section number</td>
<td>Cross references include hyperlink and bookmark</td>
<td>Cross references include CTD section number</td>
</tr>
<tr>
<td>CTD navigation through TOC and Volumes</td>
<td>eCTD navigation by XML backbone</td>
<td>CTD navigation through TOC and Volumes</td>
</tr>
<tr>
<td>Paper volume- A4</td>
<td>Layout shall be A4 or US letter size</td>
<td>Paper volume- A4</td>
</tr>
</tbody>
</table>

**CONCLUSION**

The registration and approval phase is a very crucial part of commercialization of the pharmaceutical products. As per the regulatory point of view, one has to prepare and compile the documents as per the CTD module. But other requirements like import-export code, Drug master file, and technical documentation are the supportive documents to be submitted to the regulatory body for review and approval. In this article we have covered all the certification process such as COA and COPP also actual processes like DMF filing and reviewing system, arrangements of folders in eCTD structure and differences between the CTD, eCTD, and ACTD module for better understanding in regulatory point of view.

**REFERENCES**


4. Indian Trade Portal, Pharmaceutical Industry in India. 2021, Available at: <https://www.indiantradeportal.in/vs.jsp?lang=0&id=0, 30, 50,175.>


6. Indian Trade Portal, How to Export, 2014; Available at: <https://www.indiantradeportal.in/vs.jsp?lang=0&id=0, 25, 44.>


12. ICH, CTD, 2021 Available at: <https://www.ich.org/page/ctd>.


17. ASEAN, one vision one identity one community, ASEAN Member States - 2021, Available at: <https://asean.org/asean/asean-member-states/> [Accessed 1 April 2021].


Source of Support: The author(s) received no financial support for the research, authorship, and/or publication of this article.

Conflict of Interest: The author(s) declared no potential conflicts of interest with respect to the research, authorship, and/or publication of this article.

For any question relates to this article, please reach us at: editor@globalresearchonline.net

New manuscripts for publication can be submitted at: submit@globalresearchonline.net and submit_ijpsrr@rediffmail.com